Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 8/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3243788 | 0.86 | KMT2A (0.48) | KMT2ANR1H4NR4A2 | |
| SCHEMBL30167982 | 0.85 | KMT2A (0.80) | KMT2ANR1H4NR4A2PLA2G4BAKR1C3 | |
| SCHEMBL9803295 | 0.85 | KMT2A (0.80) | KMT2ANR1H4NR4A2PLA2G4BAKR1C3 | |
| SCHEMBL10787479 | 0.85 | KMT2A (0.80) | KMT2ANR1H4NR4A2PLA2G4BAKR1C3 | |
| SCHEMBL19019858 | 0.84 | NR1H4 (0.76) | KMT2ANR1H4NR4A2PLA2G4BAKR1C3 | |
| SCHEMBL30281398 | 0.84 | NR4A2 (0.59) | KMT2ANR1H4NR4A2AKR1C3NPC1 | |
| SCHEMBL2947246 | 0.84 | NR4A2 (0.59) | KMT2ANR1H4NR4A2AKR1C3NPC1 | |
| SCHEMBL3239119 | 0.84 | MRGPRX4 (0.53) | KMT2ANR1H4POLBNPC1RAB9A | |
| SCHEMBL4509654 | 0.83 | KMT2A (0.77) | KMT2ANR1H4NR4A2PLA2G4BAKR1C3 | |
| SCHEMBL31133401 | 0.82 | KMT2A (0.71) | KMT2ANR1H4NR4A2PLA2G4BAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125087-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056195-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
| US-20100125087-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056195-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
| US-20100125087-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125087-A1 | NEW COMPOUNDS 575 | PSEN1, PSEN2, BACE1 | KMT2A 3888/4885NR1H4 2942/4885NR4A2 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.